Although the present study is the first to evaluate the serum concentrations of CT-1 in human subjects with NAFLD, the levels of CT-1 had been determined in human subjects with obesity, impaired arterial stiffness, and diabetes. Here, CTF1 is linked to metabolic dysfunction-associated steatotic liver disease.